Serial measurements of lymphocytes, D-dimer, LDH, and CRP do not improve the ability to predict COVID-19 adverse outcomes.

Jorge Pulido-ArenasDaniela Saa-GonzálezOscar Mauricio Muñoz-Velandia Alejandra Cañas-Arboleda

Published in: The Journal of international medical research (2023)

Measuring serum risk markers upon hospital admission can be used to evaluate risk of adverse outcomes in hospitalized patients with COVID-19. Repeating these measurements at 48 to 72 hours does not improve discriminatory ability.

Keyphrases

coronavirus disease
sars cov
emergency department
healthcare
peripheral blood
acute care
electronic health record
breast cancer risk